Sperm-forming stem cells in the testes can be converted to insulin-producing cells that could replace diseased ones in the pancreas, researchers from Georgetown University Medical Center in Washington, D.C., reported December 12 at the annual meeting of the American Society for Cell Biology. The new technique is edging closer to producing the amount of insulin needed to cure diabetes in humans.
Ian Gallicano, a developmental biologist at Georgetown, and his colleagues isolated sperm-producing stem cells from the testes of organ donors. These cells could easily revert to an embryonic state, capable of making nearly any cell in the body.
Cells Reprogrammed to Treat Diabetes
Autism Research: Breakthrough Discovery on the Causes of Autism
The big debate that ranges in autism circles is about whether or not autism is a fixed, irreversible brain-based genetic disorder, or a systemic, reversible body-based biological condition that has identifiable causes, measurable abnormalities, and treatable dysfunctions. In other words is autism a life sentence or a reversible condition?
Many studies have illuminated the causes and possible treatments for autism, but mainstream physicians or scientists ignore most of this data. This new study, breaks new ground because it was published in one of the world's major medical journals.
Myths and Facts: Study Verifies That There Is No Value In Any Flu Vaccine
A remarkable study published in the Cochrane Libary found no evidence of benefit for influenza vaccinations and also noted that the vast majority of trials were inadequate.
The authors stated that the only ones showing benefit were industry-funded. They also pointed out that the industry-funded studies were more likely to be published in the most prestigious journals...and one more thing: They found cases of severe harm caused by the vaccines, in spite of inadequate reporting of adverse effects.
WikiLeaks cables: Pfizer used dirty tricks to avoid clinical trial payout
The world's biggest pharmaceutical company hired investigators to unearth evidence of corruption against the Nigerian attorney general in order to persuade him to drop legal action over a controversial drug trial involving children with meningitis, according to a leaked US embassy cable. Pfizer was sued by the Nigerian state and federal authorities, who claimed that children were harmed by a new antibiotic, Trovan, during the trial, which took place in the middle of a meningitis epidemic of unprecedented scale in Kano in the north of Nigeria in 1996.
Last year, the company came to a tentative settlement with the Kano state government which was to cost it $75m.
Tobacco smoke causes immediate damage: U.S. report
Cigarette smoke causes immediate damage to the lungs and to DNA, and President Barack Obama's administration will make stop-smoking efforts a priority, federal health officials said on Thursday. Smoking hurts not only the smokers, but people around them, and taxes, bans and treatment all must be used together to help get smoking rates down, U.S. Surgeon-General Dr. Regina Benjamin said in a report on smoking.
"The chemicals in tobacco smoke reach your lungs quickly every time you inhale causing damage immediately," Benjamin said in a statement. "Inhaling even the smallest amount of tobacco smoke can also damage your DNA, which can lead to cancer."
Senate Votes One-Year Medicare Payment 'Doc Fix'
The Senate has passed a $15 billion bill that would block the impending 25% cut in the Medicare payment rate to physicians and instead keep rates steady through 2011. The cut was scheduled to take effect on Jan. 1, 2011. If the House passes the bill -- which is likely -- it would be the fifth and longest extension of Medicare physician payment rates enacted this year. And it essentially puts doctors back in the yearly "last-minute-extension" cycle Congress has followed for most of the past decade.
What the bill does not do is fix the sustainable growth rate (SGR) problem, and doctors would be subject to a cut of more than 25% for treating Medicare patients in 2012 unless Congress figures out a long-term solution in the meantime.
U.S. advisers back first new diet pill in a decade despite heart risk concerns
The first new weight-loss pill in a decade moved closer to U.S. approval on Tuesday, when a panel of expert advisers backed Orexigen Therapeutics's Contrave despite heart risk concerns. It was the third new weight-loss drug to come before U.S. regulators this year, the Food and Drug Administration having rejected two rival medicines in October.
Orexigen's stock more than doubled to $12.20 from Monday's close of $4.76 when it reopened in after-hours trade Tuesday. Shares of competitors Vivus Inc and Arena Pharmaceuticals Inc also rose, as investors bet Contrave's approval could revive their fortunes.
More Articles...
Page 127 of 232
Health Glance





























